Galle P et al. Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology front wo randomised, placebo-controlled phase 3 studies (REACH-2 and REACH). (Abstract GS-09)
Leverfunctie op lange termijn bij gevorderde of gedecompenseerde cirrose na behandeling met DAA’s
jun 2020 | Hepatitis, Hepatologie, Virale infecties